Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review

Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review

Clopidogrel is a purinergic receptor P2Y12 (P2RY12)-blocking pro-drug used to inhibit platelet aggregation in patients at risk for major adverse cardiac events (MACE), such as coronary artery disease and stroke. Despite clopidogrel therapy, some patients may still present with recurrent cardiovascul...

Full description

Bibliographic Details
Main Authors: Rahel Tekeste, Gregorio Garza, Song Han, Jianli Dong
Format: Article
Language:English
Published: AIMS Press 2022-04-01
Series:AIMS Molecular Science
Subjects:
cyp2c19
clopidogrel
p2ry12
pharmacogenetics
intermediate cyp2c19 metabolizer
mace
acs
pci
Online Access:https://www.aimspress.com/article/doi/10.3934/molsci.2022004?viewType=HTML

Internet

https://www.aimspress.com/article/doi/10.3934/molsci.2022004?viewType=HTML

Similar Items